Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6

Published on 15/05/2024 at 11:38 - Modified on 15/05/2024 at 11:43

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025	06-06	RE
Bolt Biotherapeutics, Inc. - Special Call	05-12
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-12	CI
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody ISACs Targeting Cea and PD-L1 At AACR Annual Meeting 2025	04-30	CI
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 At AACR Annual Meeting 2025	04-25	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	03-24	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	03-24	CI
Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	03-23	CI
Aadi Bioscience Appoints David Dornan, Phd, as Chief Scientific Officer	02-18	CI
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc	02-11	CI
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024	12-23	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-12	CI
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting	11-07	CI
Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors	04/09/24	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	13/08/24	CI
Bolt Biotherapeutics, Inc. Announces Management Changes	20/05/24	CI
Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	20/05/24	CI
Top Midday Decliners	15/05/24	MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	15/05/24	MT
Top Premarket Decliners	15/05/24	MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	15/05/24	MT
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	15/05/24	MT
Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05/24	MT
HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05/24	MT
Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	15/05/24	MT

BOLT BIOTHERAPEUTICS, INC.

Stock

BOLT

US0977022039

Real-time Estimate Cboe BZX Other stock markets 14:45:03 18/07/2025 BST
5.790 ^USD	+0.87%

More quotes

Chart

Duration

Period

BOLT: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Ashish Kacholia and Dolly Khanna: India's Star Investors Send Portfolio Signals

Employment figures offer some respite for the Bank of England

July 17, 2025 at 03:25 pm

Results preview: Legrand accelerates

July 17, 2025 at 10:51 am

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 10:24 am

When volatility boosts US banks

July 17, 2025 at 09:42 am

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 08:20 am

The Week's Biggest Mergers Unpacked

July 16, 2025 at 03:12 pm

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 02:29 pm

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 02:23 pm

Rare earths: Apple joins the industrial front supported by the Pentagon

July 16, 2025 at 11:16 am

All our articles